Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.

Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.

Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.

Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.

Abstract: The invention provides methods of using protein trans-splicing for the production of bispecific molecule which has a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds an antigenic molecule present in the circulatory system of a mammal. The invention also provides bispecific molecules produced by protein trans-splicing. The bispecific molecules of the invention can be used for the clearance of pathogenic antigenic molecules from the circulatory system of a mammal. The invention further provides methods of using protein trans-splicing for the production of polyclonal libraries of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal libraries of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

Abstract: The invention provides immunogenicity-reduced antibodies or antibody fragments that bind a human CR1 receptor. The immunogenicity-reduced anti-CR1 antibody of the invention comprises one or more non-human sequences modified to comprise one or more amino acid substitutions so that the immunogenicity-reduced antibody id non-immunogenic or less immunogenic to a human. The invention also provides bispecific molecules comprising such an immunogenicity-reduced anti-CR1 antibody and an antigen-recognition portion that binds a pathogen. The invention further provides methods and compositions for the treatment of diseases or disorders caused by a blood-borne immunogenic pathogen using the bispecific molecule the invention of the invention.

Abstract: The present invention provides methods and compositions related to the discovery of molecules capable of both inducing an immune response to an antigen in a mammal and also effecting clearance of the antigen, with such molecules comprising a first moiety comprising an antigen binding portion which binds specifically to complement receptor 1 (CR1) and does not substantially bind to complement receptor 2 (CR2), linked to a second moiety which comprises the antigen or binds to the antigen. Methods of producing such molecules and their therapeutic and/or prophylactic uses are also featured.

Abstract: The invention relates to a bispecific molecule comprising a first recognition binding moeity that binds a Cab-like receptor cross-linked using a poly-(ethylene glycol) (“PEG”) linker with one or more second recognition binding moieties that bind a molecule. The invention also relates to methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules.

Abstract: The present invention provide a bispecific molecule comprising an antibody that binds a C3b-like receptor linked to one or more non-neutralizing antigen-binding antibodies or fragments thereof. The present invention also provides methods to identify non-neutralizing antibodies, and particularly, to identify enhancing antibodies.

Abstract: The invention relates to a polyclonal population of bispecific molecules which comprises a plurality of different bispecific molecules, each comprising a first antigen recognition portion that binds a C3b-like receptor cross-linked to a different second antigen recognition portion that binds a pathogenic antigenic molecule such that the plurality of different bispecific molecules have different second antigen recognition portions with different recognition specificities, such as with recognition specificities directed to different epitopes and/or different variants of a pathogen and/or to different pathogens. The invention also relates to methods of producing such polyclonal population of bispecific molecules. The invention further relates to methods of using such polyclonal population of bispecific molecules for the clearance of pathogens from the circulatory system of a mammal.